Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

CureVac says aiming for pivotal vaccine trial read-out early in second quarter

FILE PHOTO: A dose of CureVac vaccine or a placebo is seen during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman

Germany's CureVac expects initial results from a late-stage trial of its COVID-19 vaccine early in the second quarter because the biotech group aims to have read-outs for specific variants.

"We need a certain number of cases for each virus variant to arrive at statistically significant results," a spokesman said on Thursday.

The company, which on Thursday added Novartis to its line-up of vaccine contract manufacturers, has previously raised the prospect of initial trial results as early as this month.

(Reporting by Ludwig Burger; Editing by Riham Alkousaa)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.